Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device
Information source: Istanbul University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Solid Tumor
Intervention: cefazolin Sodium (Drug); placebo (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Istanbul University Official(s) and/or principal investigator(s):
Hasan Karanlik, MD, Principal Investigator, Affiliation: Istanbul University Institute of Oncology Department of Surgery
Overall contact:
Hasan Karanlik, MD, Phone: +905324025354, Email: karanlik@istanbul.edu.tr
Summary
This randomized trial is determining the role of antibiotic prophylaxis in the prevention of
the infectious complications in patients carrying out totally implantable venous access
device.
Clinical Details
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial to Determine Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device.
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: infectious complication
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Older than 18 years of age
- Have solid tumor
- White cells >4000
- Platelets >100. 000
- Prothrombin time in normal range
Exclusion Criteria:
- Drug allergy
- Diabetes mellitus
Locations and Contacts
Hasan Karanlik, MD, Phone: +905324025354, Email: karanlik@istanbul.edu.tr
Istanbul University Institute of Oncology, Istanbul, Capa 34190, Turkey; Recruiting
Hasan Karanlik, MD, Email: karanlik@istanbul.edu.tr
Additional Information
Starting date: September 2008
Ending date: May 2009
Last updated: March 20, 2009
|
